Viridian Therapeutics: A Deep Dive into Its Intrinsic Value

Viridian Therapeutics, Inc. (NASDAQ: VRDN) has been making waves in the biotechnology sector with its innovative treatments for serious and rare diseases. As the company's stock price hovers around US$19.3, investors are wondering if Viridian's intrinsic value justifies this valuation. This article explores the factors influencing Viridian's intrinsic value, focusing on its clinical trial results, pipeline, and financial performance.

Viridian's clinical trial results for veligrotug, its lead drug for treating thyroid eye disease (TED), have been instrumental in shaping the company's intrinsic value. Positive phase 3 THRIVE-2 study results, announced on December 16, 2024, position Viridian to file a Biologics License Application (BLA) in the second half of 2025. This regulatory milestone could lead to marketing authorization in the U.S. and Europe, unlocking substantial revenue streams. Analysts forecast a 12-month stock price target of $36.44, representing an 88.71% increase from the current price, suggesting that VRDN's intrinsic value may be undervalued at $19.3.



Veligrotug's potential differentiation and hints of superiority over Tepezza further enhance Viridian's intrinsic value. Positive phase 3 THRIVE-2 study results position Viridian to file a BLA, with veligrotug outperforming Tepezza in early stages and targeting both active and chronic TED. This competitive advantage could lead to increased market share and revenue growth, boosting Viridian's intrinsic value beyond the current US$19.3 price.



The upcoming BLA filing for veligrotug in the second half of 2025 significantly impacts Viridian's intrinsic value and future growth prospects. The positive phase 3 THRIVE-2 study results position Viridian to file a BLA, which could lead to marketing authorization in the U.S. and Europe. This regulatory milestone could unlock substantial revenue streams, as veligrotug targets a large market with limited treatment options. The BLA filing also signals the company's progress in its pipeline, potentially attracting more investors and partnerships. As a result, the intrinsic value of Viridian Therapeutics, Inc. (NASDAQ:VRDN) may be higher than the current US$19.3 price, considering the potential market access and growth opportunities associated with veligrotug's approval.

In conclusion, Viridian Therapeutics' intrinsic value is driven by its clinical trial results, pipeline, and financial performance. Positive phase 3 THRIVE-2 study results for veligrotug, its potential differentiation from Tepezza, and the upcoming BLA filing in the second half of 2025 all contribute to a higher intrinsic value than the current stock price of US$19.3. As Viridian continues to advance its pipeline and generate positive data, investors may want to consider the company's intrinsic value when evaluating its investment potential.